









   
  
       
 
ABSTRACT 
Objective: A substantial fraction of the population is intolerant or does not respond well to the recommended treatments for dyslipidemia. The 
purpose of this study was to evaluate the efficacy of gamma-oryzanol (γ-ORZ) treatment in acute and long-term mouse experimental models of 
dyslipidemia in comparison to Gemfibrozil and Simvastatin. 
Methods: For the acute dyslipidemia-induced model, dyslipidemia was induced in 40 mice using a single intra-peritoneal administration of Triton 
WR-1339. For the long-termmodel, dyslipidemia was induced in 24 mice using a hypercholesterolemic diet over 14 days. Thereafter, animals were 
divided into different groups of treatment, and orally received treatments with gamma-oryzanol (5, 25, 50mg. kg
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), gemfibrozil or simvastatin. For 
biochemical analysis, glucose, total cholesterol and triacylglycerols were measured. Body weight and net food intake was registered weekly, and 
urea, creatinine, AST and ALT levels were evaluated. The data were analyzed by analysis of variance (ANOVA), followed by the Student-Newman-
Keuls method,and p value of less than 0.05 was considered significant. 
Results: Only the highest dose of γ-ORZ exhibited significant protective effects. Gamma-oryzanol and Gemfibrozil treatments reduced total 
cholesterol and triacylglycerols levels in a similar manner in the acute model. In the second model, γ-ORZ and simvastatin treatments reduced 
glucose and total cholesterol levels in the same way. In addition, the administration ofγ-ORZ did not cause any adverse events, or significantly 
altered hepatic enzymes levels, plasmatic urea or creatinine concentrations. 
Conclusion: The results of this study suggest that gamma-oryzanol acts as a potential lipid-lowering agent, reducing triglycerides and total 
cholesterol in dyslipidemia-induced models. 
Keywords: Dyslipidemia, Gamma-oryzanol, Statin, Fibrate, Cholesterol, Triglycerides, Glucose, Lipid-lowering. 
Dyslipidemia is considered a major risk factor for cardiovascular 
disease (CVD)[1, 2], which is the leading cause of years of life lost 
(YLL)worldwide[3]. Statins and fibrates are the first-line drugs for 
treatment of dyslipidemia [4, 5],and have been used for decades as 
lipid-lowering agents to improve several lipid and lipoprotein 
parameters[6, 7]. However, a substantial fraction of the population is 
intolerant or do not respond appropriately to these drugs [8, 9]. 
Myopathy, hypersensitivity skin reactions, headaches, pancreatitis, 
hepatitis, sexual dysfunction, and gastrointestinal and sleep 
disturbances are common adverse effects related with the use of 
these drugs [10]. Thus, the development of new therapeutic agents 
with equivalent effects remains important. Natural compounds, such 
as phytosterol and oryzanol, have been shown to exhibit potent 
cholesterol-lowering effects in previously reported animal and human 
studies [11-16]. Rice bran oil (RBO) is not commonly used oil 
worldwide, but is in steady demand as a so-called "healthy oil" in Asian 
countries, particularly India. Gamma-oryzanol (γ-ORZ)is a major 
component of RBO, and it is a mixture of ferulic acid esters of 
triterpene alcohols, such as cycloartenol (106 mg%) and 24-methylene 
cycloartanyl (494 mg%)[17, 18].  
It has been reported to produce both hypocholesterolemic and 
hypolipoproteinemic activities, to reduce the risk of CVD and to 
possess anti-oxidative properties [19], but no studies to date have 
compared its lipid-lowering effect with currently used drugs. The 
purpose of this study was to evaluate the efficacy of γ-ORZ treatment 
in acute and long-termmouse experimental models of dyslipidemia in 
comparison to two commonly used drugs (Gemfibrozil and 
Simvastatin) and with a view to developing an alternative treatment. 
MATERIALS AND METHODS 
Experimental animals 
Male Swiss mice weighing 25-30 g were obtained from the Central 
Animal House of The Federal University of Ceará and the 
Department of Physiology and Pharmacology. Animals were kept in 
propylene cages at a room temperature of 24 ± 2ºC and on a 12 h 
light/dark cycle with food and water provided ad libitum unless 
otherwise noted. The mice were fed with a standard laboratory 
chow(Nuvilab®
For the acute dyslipidemia-induced model, dyslipidemia was 
induced using a single intra-peritoneal administration of Triton WR-
 CR1, Brasil) for two weeks for environmental 
adaptation (control diet, Table 1). 
All experimental protocols were approved by the Federal University 
of Ceará Institutional Committee on Care and Use of Animals for 
experimentation, (protocol no. 90/10) and in accordance with the 
guidelines of the National Institutes of Health, Bethesda, MD. 
Chemicals 
Tween 80, Triton WR-1339 and γ-oryzanol were purchased from 
Sigma-Aldrich Co. (St. Louis, MO - USA). Simvastatin and 
gemfibrozilwere purchased from Merck & Co., Inc. (Whitehouse 
Station, NJ - USA). 
Study design 
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1339 (400 mg. kg-1 20), as previously reported [ , 21]. 48 animals 
were used. The control group (CTL) received a single intra-
peritoneal administration of 0,9% NaCl solution (10 µL. g-1). 
Thereafter, animals were divided into6 groups (n = 8 each) and 
orally received the following treatments: Control (vehicle); T1339 
(vehicle); GEMF (gemfibrozil100 mg. kg-1); 5γ-ORZ (γ-oryzanol 5 mg. 
kg-1); 25γ-ORZ (γ-oryzanol, 25 mg. kg-1); and 50γ-ORZ (γ-oryzanol 
50 mg. kg-1
For the long-term dyslipidemia-induced model, dyslipidemia was 
induced using a hypercholesterolemic diet over 14 days, as reported 
by 
). The groups received the treatment three times: 1 hour 
before Triton WR-1339 administration and 22 and 46 hours after 
induction. Gamma-oryzanol and gemfibrozil were suspended in 3% 
(v/v) Tween 80 and then in water. The mice were fasted for 8 h 
before blood sampling. 24 h and 48 h following the Triton induction, 
blood samples were collected and centrifuged (15 min, 2,400 x g, 
RT) to obtain plasma.  
Wilson, Nicolosi [22]. 32 animals were used. Animals were 
dividedinto4 groups (n = 8 each) in accordance with their total 
cholesterol levels and were treated for 2 months as follows: CTL 
(normal diet + vehicle, p. o.), HCD (hypercholesterolemic diet + 
vehicle, p. o.),50γ-ORZ (hypercholesterolemic diet+ γ-oryzanol 50 




, p. o.). The concentrations chosen for γ-ORZ were based on 
the results observed in the acute model. Gamma-oryzanol and SIMV 
were suspended in 3% (v/v) Tween 80 in water. HCD controls 
received the same vehicle. After each month of treatment, the 
animals were fasted for 8 h, and then blood samples were collected 
for biochemical analysis. 
 
Table 1: Diet Formulations 
Control Diet Hypercholesterolemic Diet 
g% Kcal% g% kcal% 
Protein 22 25 19,5 19 
Carbohydrate 57 65 51 51 
Fat 4 10 13,5 30 
Cholesterol 0 0 1,1 0 
Vitamin, 
mineral, other 
9,5 0 8,5 0 
Humidity 7,5 0 6,4 0 
 
For biochemical analysis, glucose, total cholesterol and 
triacylglycerols were measured using commercially enzymatic 
kitsGlicose GOD, ColesterolLiquiform and TriglicéridesLiquiform 
(LabtestDiagnóstica, Brazil). In addition to these,body weight, net 
food intake was registered weekly and urea, creatinine, AST and ALT 
levels were measured by commercial kitsUréia CE, CK-NAC 
Liquiform, AST/GOT Liquiform and ALT/GPT Liquiform 
(LabtestDiagnóstica, Brazil), respectively. 
Statistical analysis 
The results are presented as the mean ± standard error of the mean 
(SEM). The data were analyzed by analysis of variance (ANOVA), 
followed by the Student-Newman-Keuls method. P value of less than 
0.05 was considered significant. 
RESULTS  
Intra-peritoneal injection of Triton WR-1339 clearly induced 
dyslipidemia, characterized by an increase in blood glucose, total 
cholesterol (TC) and triacylglycerols (TG).24 h after induction, there 
was a statistically significant increase in blood glucose (70 %), TC (310 
%) and TG (4925 %) 
Among doses of γ-ORZ tested (5, 25 and 50 mg. kg
(Figure 1A) in the T1339 group compared to 
control.  
-1), only the 
highest dose exhibited significant protective effects. Mice treated 
with 50 mg γ-ORZ showed a statistically significant (25 %) reduction 
in blood glucose levels when compared to the T1339 group, whereas 
there was no change in the GEMF group. Both 50 γ-ORZ and GEMF 
significantlyreducedthe TC and TGin comparison to the T1339 group 
(Figure 1B and 1C
 
). Even at 48 h after induction, the T1339 group 
showed higher levels of GLU, TC and TG when compared to the CTL 
group. In addition, the 50γ-ORZ group exhibited significantly 
reduced levels of all the parameters, approaching levels similar to 
those measured in the CTL group. Fig. 1 
After the first month of the hypercholesterolemic diet-induced 
dyslipidemia model, the HCD group showed a statistically significant 
increase in glucose levels (20 %) compared to animals that received 
a normal diet (CTL). HCD efficiently increased cholesterolemia levels 
in all groups (47 %) compared to the CTL group. However, 
somewhat unexpected was the observation that triglyceride levels 
were reduced in the HCD group compared to CTL. 
The 50γ-ORZ-treated animals showed a statistically significant 
reduction of 22 % in cholesterolemia levels when compared to the 
HCD mice, reaching levels similar to those in the CTL mice. In 
addition, the hypercholesterolemic diet nearly doubled (188 %) 
cholesterolemia in the HCD group. SIMV effectively reduced the total 
cholesterol (14 %) compared to the HCD group. Mice receiving the 
50γ-ORZ treatment exhibited a greater reduction in total cholesterol 
of around30%. 
Fig. 1: γ-ORZ reduces triglycerides and total cholesterol 
similarly to the fibrate drug Gemfibrzil. A) Glucose, B) TG and C) 
TC 
Values represent the mean ± SEM (n=8). γ-Oryzanol(γ-ORZ); 
gemfibrozil(GEMF). The groups that statistically differed from 
CTL and from T1339 were marked as (●) and (■), respectively. 
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Fig. 2: γ-ORZ reduces glucose and total cholesterol similarly to 
the drug simvastatin. Control diet (CTL); hypercholesterolemic 
diet (HCD); 50 mg. kg-1
To evaluate the acute effects of γ-ORZ on cholesterolemia and 
triacylglycerolemia, dyslipidemia was induced with Triton WR1339. 
This nonionic detergent acts to prevent the catabolism of 
triacylglycerol-rich lipoproteins by lipoprotein lipase (LPL)[
 γ-oryzanol dose (50γ-ORZ); simvastatin 
(SIMV). Each value represents the mean ± SEM. The groups that 
statistically differed from CTL and from HCD were marked as 
(*) and (§), respectively. 
 
There were no statistically significant differences in final body 
weights among the groups. However, an increase in the net food 
consumption in animals receiving the HCD was observed compared 
to those who received the CTL. No side effects were observed in any 
of the groups. The urea plasmatic levels were significantly higher in 
the HCD mice when compared to the CTL. Nevertheless, this increase 
in urea levels was reversed by the γ-ORZ and SIMV treatments. No 
significant changes were observed in the levels of AST, ALT or 
creatinine in the studied groups (data not shown). 
DISCUSSION 
The study presented here sought to evaluate the efficacy of γ-ORZ as 
a lipid-lowering drug, and compared it to existing drugs commonly 
used to treat dyslipidemia. Results presented here clearly show that 
γ-ORZ efficiently reduced blood triglycerides level and total 
cholesterol in dyslipidemia models. 
23, 24] 
and is frequently used for the in vivo determination of triacylglycerol 
production, and VLDL secretion or clearance rate[20]. Using this 
established model[20, 23, 24], gamma-oryzanol was compared with 
Gemfibrozil, which is the recommended lipid-lowering agent for 
treatment of severe hypertriglyceridemia [25, 26]. Results showed that 
both treatments reduced total cholesterol and triacylglycerols levels in 
a similar manner.  
To evaluate the efficacy of regular supplementation of γ-ORZ, 
dyslipidemia was also induced through a hypercholesterolemic diet 
and its effects were compared with Simvastatin, which is the 
recommended drug in the treatment of isolated 
hypercholesterolemia [25, 26]. Results showed that both treatments 
reduced glucose and total cholesterol levels in a similar manner. 
Interestingly, all groups that received the hypercholesterolemic diet 
showed a significant reduction in the triacylglycerol levels compared 
to the normal diet group. A similar effect has been previously 
observed in coconut oil fed animals, that showed a significant 
reduction in the serum and tissue triacylglycerol levels and a 
decrease in the activity of glucose-6-phosphatase dehydrogenase 
[27]. However, no mechanism has been suggested and more 
research is needed to explain this finding. Regardless of this 
accidental finding, results presented here clearly showed that total 
cholesterol was significantly reduced by both γ-ORZ and simvastatin 
to a similar extent. 
These findings are in line with numerous previous studies reporting 
several physiological effects associated with γ-ORZ. These include 
the reduction of plasma cholesterol, the reduction of hepatic 
cholesterol biosynthesis, the reduction of high-fat diet induced 
cardiovascular disease, and the increase offecal excretion of biliary 
acids [28-30]. Several mechanisms have been proposed to explain 
these effects. For exampleMakynen, Chitchumroonchokchai [31] 
have suggested that the hypocholesterolemic activity of γ-ORZ is due 
in part to impaired apical uptake of cholesterol into enterocytes and 
perhaps a decrease in HMG-CoA reductase activity. Indeed, 
elucidating the exact mechanisms involved in the lipid-lowering 
activity of γ-ORZ may be valuable for designing future 
pharmacologically active agents to tackle dyslipidemia. 
The results presented here also showed γ-ORZ to be safe. Its 
administration did not cause any adverse events or significantly 
altered hepatic enzymes levels (ALT and AST), plasmatic urea or 
creatinine concentrations. However, the potential side effects of 
gamma oryzanol are not yet known and more research is necessary 
to establish toxicological and side effects of this natural compound.  
This study is somewhat limited by the reduced number of doses of 
gamma-oryzanol employed. Nevertheless, to our knowledge, this is 
the first attempt to compare the efficacy ofγ-ORZ with the current 
standard treatments for the management of dyslipidemia.  
CONCLUSION 
The results of this study suggest that50 mg. kg-1
1. Gotto AM Jr, Moon JE. Management of cardiovascular risk: the 
importance of meeting lipid targets. Am J Cardiol 2012;110(1 
Suppl):3A-14A. 
gamma-oryzanol 
acts as a potential lipid-lowering agent in a manner equivalent to 
Simvastatin and Gemfibrozil, reducing triglycerides and total 
cholesterol at dyslipidemia-induced models. Whilst additional 
studies are needed to prove its safety, γ-oryzanol has potential tobe 
used as a complementary or alternative treatment for those patients 
who cannot achieve desired targets or who are intolerant to existing 
drugs. 
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